Glenmark arm nets Rs 180 cr in licensing deal for autoimmune antibody

ISB 880 has the potential to treat underserved patients across a range of autoimmune dermatological diseases

Glenmark subsidiary Ichnos Sciences, a biotechnology company that develops biologics in oncology and autoimmune diseases, has licensed the commercialisation rights of a monoclonal antibody for autoimmune diseases to Almirall for €20.8 million (around Rs 180 crore).

Under the agreement, Almirall is granted global rights to develop and commercialise the ISB 800 molecule. However, Ichnos will retain rights for antibodies acting on the  IL-1RAP pathway for oncology indications. Ichnos will receive an upfront payment of €20.8 million as well as additional development and commercial milestone payments and tiered royalties based upon future global sales.

“This is our eighth out-licensing deal in